Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
Affluent Medical
Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
04-Apr-2024 / 17:45 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Affluent Medical announces coverage initiation
of its stock by Gilbert Dupont – Société Générale Group
Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.
Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024. In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.
This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, Portzamparc BNP Paribas Group, and TP ICAP Midcap.
About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary incontinence, which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions. The product candidates developed by the Company are currently all in clinical studies.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies, the Company's ambition is to gradually commercialize its products early 2026.
For more information, visit www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL
Sébastien Ladet
Chief Executive Officer
SEITOSEI.ACTIFIN
Financial communications / press relations
Ghislaine GASPARETTO / Jennifer JULLIA
+33 (0)6 21 10 49 24 / +33 (0)1 56 88 11 19
ghislaine.gasparetto@seitosei-actifin.com / jennifer.jullia@seitosei-actifin.com
PRIMATICE
Media relations France
Thomas Roborel de Climens
+33 (0)6 78 12 97 95
MC SERVICES AG
Media relations Europe
Caroline Bergmann / Kirsten RÜHL
+49 (0)211 529252 20 / +49 (0)211 529252 16
affluent@mc-services.eu
File: 20240404_Affluent Medical_PR_SOCGEN coverage initiation
Language: English Company: Affluent Medical 320 avenue Archimède, Les pléiades III Bâtiment B 13100 Aix en Provence France France Phone: +33 4 42 95 12 20 E-mail: jerome.geoffroy@affluentmedical.com Internet: https://www.affluentmedical.com/ ISIN: FR0013333077 Euronext Ticker: AFME AMF Category: Inside information / Other releases EQS News ID: 1873727 End of Announcement EQS News Service
1873727 04-Apr-2024 CET/CEST